These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25453753)

  • 41. Inhibition of EGFR Activation by Bivalent Ligands Based on a Cyclic Peptide Mimicking the Dimerization Arm Structure of EGFR.
    Toyama K; Kobayakawa T; Nomura W; Tamamura H
    Chem Pharm Bull (Tokyo); 2018; 66(11):1083-1089. PubMed ID: 30381661
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Membrane interaction of bound ligands contributes to the negative binding cooperativity of the EGF receptor.
    Arkhipov A; Shan Y; Kim ET; Shaw DE
    PLoS Comput Biol; 2014 Jul; 10(7):e1003742. PubMed ID: 25058506
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of the diffusion of epidermal growth factor receptor clusters by single particle tracking.
    Boggara M; Athmakuri K; Srivastava S; Cole R; Kane RS
    Biochim Biophys Acta; 2013 Feb; 1828(2):419-26. PubMed ID: 22974816
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Allosteric activation of preformed EGF receptor dimers by a single ligand binding event.
    Purba ER; Saita EI; Akhouri RR; Öfverstedt LG; Wilken G; Skoglund U; Maruyama IN
    Front Endocrinol (Lausanne); 2022; 13():1042787. PubMed ID: 36531494
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of N-glycans in growth factor signaling.
    Takahashi M; Tsuda T; Ikeda Y; Honke K; Taniguchi N
    Glycoconj J; 2004; 20(3):207-12. PubMed ID: 15090734
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Emerging Allosteric Mechanism of EGFR Activation in Physiological and Pathological Contexts.
    Tsai CJ; Nussinov R
    Biophys J; 2019 Jul; 117(1):5-13. PubMed ID: 31202480
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular Mechanism Regarding Allosteric Modulation of Ligand Binding and the Impact of Mutations on Dimerization for CCR5 Homodimer.
    Zhang F; Yuan Y; Xiang M; Guo Y; Li M; Liu Y; Pu X
    J Chem Inf Model; 2019 May; 59(5):1965-1976. PubMed ID: 30688454
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comprehensive Model for Epidermal Growth Factor Receptor Ligand Binding Involving Conformational States of the Extracellular and the Kinase Domains.
    Hajdu T; Váradi T; Rebenku I; Kovács T; Szöllösi J; Nagy P
    Front Cell Dev Biol; 2020; 8():776. PubMed ID: 32850868
    [TBL] [Abstract][Full Text] [Related]  

  • 49. EGFR Mutations in GBM Alter Ligand Binding and Subsequent Dimerization.
    Cancer Discov; 2022 Apr; 12(4):884. PubMed ID: 35373268
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The juxtamembrane region of EGFR takes center stage.
    Hubbard SR
    Cell; 2009 Jun; 137(7):1181-3. PubMed ID: 19563749
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dimerization-based control of cooperativity.
    Bouhaddou M; Birtwistle MR
    Mol Biosyst; 2014 Jul; 10(7):1824-32. PubMed ID: 24736836
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Putting together structures of epidermal growth factor receptors.
    Bessman NJ; Freed DM; Lemmon MA
    Curr Opin Struct Biol; 2014 Dec; 29():95-101. PubMed ID: 25460273
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Investigating extracellular in situ EGFR structure and conformational changes using FRET microscopy.
    Roberts SK; Tynan CJ; Winn M; Martin-Fernandez ML
    Biochem Soc Trans; 2012 Feb; 40(1):189-94. PubMed ID: 22260688
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A 45-Amino-Acid Scaffold Mined from the PDB for High-Affinity Ligand Engineering.
    Kruziki MA; Bhatnagar S; Woldring DR; Duong VT; Hackel BJ
    Chem Biol; 2015 Jul; 22(7):946-56. PubMed ID: 26165154
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glioma Specific Extracellular Missense Mutations in the First Cysteine Rich Region of Epidermal Growth Factor Receptor (EGFR) Initiate Ligand Independent Activation.
    Ymer SI; Greenall SA; Cvrljevic A; Cao DX; Donoghue JF; Epa VC; Scott AM; Adams TE; Johns TG
    Cancers (Basel); 2011 Apr; 3(2):2032-49. PubMed ID: 24212795
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cooperativity and anti-cooperativity between ligand binding and the dimerization of ristocetin A: asymmetry of a homodimer complex and implications for signal transduction.
    Cho YR; Maguire AJ; Try AC; Westwell MS; Groves P; Williams DH
    Chem Biol; 1996 Mar; 3(3):207-15. PubMed ID: 8807847
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibiting EGFR dimerization using triazolyl-bridged dimerization arm mimics.
    Hanold LE; Oruganty K; Ton NT; Beedle AM; Kannan N; Kennedy EJ
    PLoS One; 2015; 10(3):e0118796. PubMed ID: 25790232
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cooperativity transitions driven by higher-order oligomer formations in ligand-induced receptor dimerization.
    Watabe M; Arjunan SNV; Chew WX; Kaizu K; Takahashi K
    Phys Rev E; 2019 Dec; 100(6-1):062407. PubMed ID: 31962468
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Absolute Ligand Discrimination by Dimeric Signaling Receptors.
    Fathi S; Nayak CR; Feld JJ; Zilman AG
    Biophys J; 2016 Sep; 111(5):917-20. PubMed ID: 27602720
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Thresholds and ultrasensitivity from negative cooperativity.
    Ha SH; Ferrell JE
    Science; 2016 May; 352(6288):990-3. PubMed ID: 27174675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.